Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 19/20 | 0.69 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180927 | 1.00 | DGAT1 (0.69) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL14617044 | 1.00 | DGAT1 (0.69) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL13664087 | 1.00 | DGAT1 (0.69) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL181065 | 0.88 | DGAT1 (0.51) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL12203215 | 0.85 | DGAT1 (0.47) | DGAT1 | |
| SCHEMBL181168 | 0.85 | DGAT1 (0.81) | DGAT1SOAT1 | |
| SCHEMBL181129 | 0.85 | DGAT1 (0.75) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL180830 | 0.84 | DGAT1 (0.76) | DGAT1SOAT1 | |
| SCHEMBL180809 | 0.82 | DGAT1 (0.82) | DGAT1SOAT1 | |
| SCHEMBL31326545 | 0.82 | DGAT1 (0.82) | DGAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SOAT1 4/4885FAAH 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.